Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 CAR-T Cell Injection in Inflammatory Bowel Disease
NCT07309744Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in ulcerative colitis (UC) and Crohn's disease. Primary endpoint: Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 24 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
RD06-05
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT07309744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309744.